NASDAQ:BCAB BioAtla - BCAB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.68 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.62▼$3.7750-Day Range$3.18▼$11.0152-Week Range$2.01▼$12.15Volume230,776 shsAverage Volume1.50 million shsMarket Capitalization$138.39 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioAtla MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside375.5% Upside$17.50 Price TargetShort InterestHealthy8.64% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 3 Articles This WeekInsider TradingAcquiring Shares$47,361 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.96) to ($2.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector93rd out of 1,055 stocksBiological Products, Except Diagnostic Industry19th out of 170 stocks 3.4 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, BioAtla has a forecasted upside of 375.5% from its current price of $3.68.Amount of Analyst CoverageBioAtla has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.64% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioAtla has recently decreased by 21.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 3.0 News and Social Media Coverage News SentimentBioAtla has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioAtla this week, compared to 1 article on an average week.Search Interest16 people have searched for BCAB on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.MarketBeat Follows2 people have added BioAtla to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,361.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.80% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.15% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($2.96) to ($2.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioAtla (NASDAQ:BCAB) StockBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Read More Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Stock News HeadlinesJanuary 25, 2023 | finance.yahoo.comRecent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past yearDecember 8, 2022 | finance.yahoo.comBioAtla, Inc.'s stock is down 11%, but insiders still have about US$393k in profit after buying earlier this yearJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 1, 2022 | finance.yahoo.comDoes BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?November 15, 2022 | finance.yahoo.comCan BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?November 11, 2022 | finance.yahoo.comCompanies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In GrowthNovember 8, 2022 | finance.yahoo.comBioAtla to Participate in the Jefferies London Healthcare ConferenceNovember 7, 2022 | seekingalpha.comBioAtla, Inc. (BCAB) Q3 2022 Earnings Call TranscriptJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 4, 2022 | finance.yahoo.comBioAtla Announces $65 Million Underwritten Offering of its Common StockNovember 4, 2022 | finance.yahoo.comBioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue EstimatesOctober 27, 2022 | finance.yahoo.comBioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022October 17, 2022 | nasdaq.comHere's Why We're Not Too Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation - NasdaqSeptember 23, 2022 | seekingalpha.comBioAtla: Back From The Dead (NASDAQ:BCAB) - Seeking AlphaSeptember 22, 2022 | nasdaq.comJ.P. Morgan Says Stock Market Downside Risk Is Limited; Here Are 3 Stocks to Consider - NasdaqSeptember 21, 2022 | finance.yahoo.comJ.P. Morgan Says Stock Market Downside Risk Is Limited; Here Are 3 Stocks to Consider - Yahoo FinanceSeptember 12, 2022 | benzinga.comBioAtla (NASDAQ:BCAB) – Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (H - BenzingaAugust 23, 2022 | benzinga.comWhy MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday’s Mid-Day Session - BenzingaAugust 23, 2022 | seekingalpha.comBioAtla Stock: Promising Signal In NSCLC, But Concerns Remain (NASDAQ:BCAB) - Seeking AlphaAugust 18, 2022 | finance.yahoo.comDo Insiders Own Lots Of Shares In BioAtla, Inc. (NASDAQ:BCAB)?August 17, 2022 | nasdaq.comWhat Type Of Shareholders Make Up BioAtla, Inc.'s (NASDAQ:BCAB) Share Registry? - NasdaqAugust 14, 2022 | seekingalpha.comBioatla (BCAB) Investor Presentation - SlideshowAugust 13, 2022 | seekingalpha.comBioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results - Earnings Call TranscriptAugust 10, 2022 | in.investing.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.63% - Investing.com IndiaAugust 10, 2022 | seekingalpha.comBioAtla rises 39% as Q2 net loss narrows (NASDAQ:BCAB) - Seeking AlphaAugust 10, 2022 | finance.yahoo.comBioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress - Yahoo FinanceAugust 10, 2022 | finance.yahoo.comBioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Company Calendar Last Earnings11/04/2022Today1/27/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.50 High Stock Price Forecast$25.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+375.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.78% Return on Assets-46.11% Debt Debt-to-Equity RatioN/A Current Ratio7.69 Quick Ratio7.69 Sales & Book Value Annual Sales$250,000.00 Price / Sales553.58 Cash FlowN/A Price / Cash FlowN/A Book Value$5.65 per share Price / Book0.65Miscellaneous Outstanding Shares37,607,000Free Float32,041,000Market Cap$138.39 million OptionableNot Optionable Beta0.65 Key ExecutivesDr. Jay M. Short Ph.D. (Age 65)Co-Founder, CEO & Chairman Comp: $1.02MMr. Scott Andrew Smith (Age 61)Pres & Director Comp: $798.89kMr. Richard A. Waldron (Age 69)Chief Financial Officer Comp: $593.51kDr. Eric L. Sievers M.D. (Age 59)Chief Medical Officer Comp: $552.62kMr. Christian Vasquez (Age 48)VP of Fin., Corp. Controller & Sec. Comp: $345.88kMr. Philippe Martin (Age 47)Chief Clinical Devel. & Operations Lisa M. PeltonAccounting Mang.Ms. Susie MelodySr. VP of HRDr. Cathy Chang Ph.D.Sr. VP of R&DMs. Monica SullivanSr. VP of Intellectual Property & ContractsMore ExecutivesKey CompetitorsIkena OncologyNASDAQ:IKNAVaxartNASDAQ:VXRTINmune BioNASDAQ:INMBCellectisNASDAQ:CLLSAthira PharmaNASDAQ:ATHAView All CompetitorsInsiders & InstitutionsSylvia McbrinnBought 3,700 shares on 12/19/2022Total: $30,821.00 ($8.33/share)Bank of New York Mellon CorpBought 13,150 shares on 12/8/2022Ownership: 0.035%Toroso Investments LLCSold 88,591 shares on 11/23/2022Ownership: 0.109%Sylvia McbrinnBought 2,000 shares on 11/22/2022Total: $16,540.00 ($8.27/share)Fred Alger Management LLCBought 41,171 shares on 11/16/2022Ownership: 0.109%View All Insider TransactionsView All Institutional Transactions BCAB Stock - Frequently Asked Questions Should I buy or sell BioAtla stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks. What is BioAtla's stock price forecast for 2023? 4 equities research analysts have issued 12-month price objectives for BioAtla's shares. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 369.2% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts. How have BCAB shares performed in 2023? BioAtla's stock was trading at $8.25 at the beginning of 2023. Since then, BCAB stock has decreased by 54.8% and is now trading at $3.73. View the best growth stocks for 2023 here. Are investors shorting BioAtla? BioAtla saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,250,000 shares, a decrease of 21.9% from the December 31st total of 4,160,000 shares. Based on an average trading volume of 880,600 shares, the short-interest ratio is presently 3.7 days. View BioAtla's Short Interest. When is BioAtla's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our BCAB earnings forecast. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) posted its earnings results on Friday, November, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.08. When did BioAtla IPO? (BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. What is BioAtla's stock symbol? BioAtla trades on the NASDAQ under the ticker symbol "BCAB." How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioAtla's stock price today? One share of BCAB stock can currently be purchased for approximately $3.73. How much money does BioAtla make? BioAtla (NASDAQ:BCAB) has a market capitalization of $140.27 million and generates $250,000.00 in revenue each year. The company earns $-95,400,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. How can I contact BioAtla? The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com. This page (NASDAQ:BCAB) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.